Remove 2014 Remove Compliance Remove Informed Consent
article thumbnail

FDA Finalizes Its Informed Consent Guidance for IRBs, Clinical Investigators and Sponsors

Hall Render

Food and Drug Administration (“FDA”) finalized “ Informed Consent: Guidance for IRBs, Clinical Investigators, and Sponsors ” (“Final Guidance”), following the FDA’s earlier issuance of draft guidance on the subject in July 2014.

article thumbnail

SQA Regulatory Surveillance Summary 3 | Monthly Update 2021

SQA

generic, biosimilar, or hybrid application), informed consent is irrelevant provided that both applications relate to a medicinal product with the same qualitative and quantitative composition in active substances and the same pharmaceutical form. European Medicines Agency (EMA) – Biologics.

article thumbnail

Guest Post – Curling Up With a Good Reasonable Alternative Design Opinion

Drug & Device Law

Fajardo held that Plaintiffs’ email was not in technical compliance with Connecticut rules of procedure and was especially critical of Plaintiffs for failing to cite any evidence in that email, which would have warranted a denial of their request. at *20 (citing Casey v. Toyota Motor Engineering & Mfg. 3d 322, 331 (5th Cir. at *13-*14.